Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ABSI
stocks logo

ABSI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.42M
+113.35%
-0.176
-29.44%
3.44M
+192.02%
-0.165
-21.43%
4.16M
+601.04%
-0.168
-30.21%
Estimates Revision
The market is revising Downward the revenue expectations for Absci Corporation (ABSI) for FY2025, with the revenue forecasts being adjusted by -24.26% over the past three months. During the same period, the stock price has changed by 51.63%.
Revenue Estimates for FY2025
Revise Downward
down Image
-24.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.88%
In Past 3 Month
Stock Price
Go Up
up Image
+51.63%
In Past 3 Month
Wall Street analysts forecast ABSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABSI is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast ABSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABSI is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.730
sliders
Low
7.00
Averages
8.00
High
10.00
Current: 3.730
sliders
Low
7.00
Averages
8.00
High
10.00
Morgan Stanley
Overweight
downgrade
$7
2025-07-27
Reason
Morgan Stanley
Price Target
$7
2025-07-27
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Absci to $6.40 from $7 and keeps an Overweight rating on the shares after the company announced a $50M public offering. The firm modeled a new share count and cash.
Morgan Stanley
Overweight
initiated
$7
2025-07-03
Reason
Morgan Stanley
Price Target
$7
2025-07-03
initiated
Overweight
Reason
Morgan Stanley assumed coverage of Absci with an Overweight rating and $7 price target. Absci has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. The upcoming value inflection points with the second half of 2025 interim data readout for TL1A asset ABS-101 and second half of 2026 Phase I interim proof of concept efficacy readout for PRLR ABS-201 present potential results skewed to the upside for Absci, the firm says.
Keybanc
Scott Schoenhaus
Buy
Maintains
$5 → $9
2025-04-16
Reason
Keybanc
Scott Schoenhaus
Price Target
$5 → $9
2025-04-16
Maintains
Buy
Reason
KeyBanc raised the firm's price target on Absci to $9 from $5 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.
Needham
Gil Blum
Strong Buy
Reiterates
$9
2025-04-09
Reason
Needham
Gil Blum
Price Target
$9
2025-04-09
Reiterates
Strong Buy
Reason
Guggenheim
Vamil Divan
Strong Buy
Reiterates
$10
2025-03-20
Reason
Guggenheim
Vamil Divan
Price Target
$10
2025-03-20
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$7
2025-03-19
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$7
2025-03-19
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Absci Corp (ABSI.O) is -5.84, compared to its 5-year average forward P/E of -5.66. For a more detailed relative valuation and DCF analysis to assess Absci Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.66
Current PE
-5.84
Overvalued PE
-0.11
Undervalued PE
-11.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.66
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.45
Undervalued EV/EBITDA
-11.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
43.65
Current PS
0.00
Overvalued PS
84.65
Undervalued PS
2.65
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 1029.38% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ABSI News & Events

Events Timeline

(ET)
2025-12-04
08:10:00
Absci Initiates Phase 1/2a Trial for ABS-201
select
2025-11-12 (ET)
2025-11-12
16:29:11
Absci anticipates sufficient cash to support operations through the first half of 2028.
select
2025-11-12
16:27:30
Absci Announces Q3 EPS of 20 Cents, Below Consensus Estimate of 21 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04Globenewswire
Absci Initiates ABS-201 Clinical Trial with Interim Data Expected in Mid-2026
  • Clinical Trial Launch: Absci has dosed the first healthy volunteers in its Phase 1/2a HEADLINE study of ABS-201, with interim data expected in the second half of 2026, marking a significant advancement in regenerative biology for the company.
  • Innovative Treatment Pathway: ABS-201 targets the prolactin receptor to treat androgenetic alopecia and endometriosis, offering a potential best-in-class solution that could significantly enhance patient quality of life.
  • Optimized Trial Design: The clinical trial will enroll up to 227 healthy volunteers primarily assessing safety and tolerability, and successful outcomes will pave the way for accelerated registrational trials, showcasing the company's efficiency in clinical development.
  • Market Opportunity Discussion: Absci will host a KOL seminar on December 11 to discuss the clinical development path and market opportunities for ABS-201, further emphasizing its differentiated advantages in the treatment landscape.
[object Object]
Preview
9.5
11-14NASDAQ.COM
Transcript of Absci (ABSI) Earnings Call for Q3 2025
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
2.0
11-13Benzinga
Major Stocks Including Ardent Health, KinderCare Learning, and Ibotta Decline in Thursday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures up by approximately 0.1% on Thursday morning.

  • Ardent Health Earnings Report: Ardent Health, Inc. experienced a significant drop in pre-market trading after reporting third-quarter losses of 17 cents per share, missing analyst expectations, and lowering its FY2025 GAAP EPS guidance.

  • Other Stocks Declining: Several other companies, including WEBTOON Entertainment and KinderCare Learning Companies, saw substantial declines in pre-market trading due to disappointing earnings and lowered sales guidance.

  • Market Reactions: Various stocks, such as Bitdeer Technologies and Absci Corp, also faced declines in pre-market trading following mixed quarterly results or negative announcements.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Absci Corp (ABSI) stock price today?

The current price of ABSI is 3.73 USD — it has increased 13.37 % in the last trading day.

arrow icon

What is Absci Corp (ABSI)'s business?

Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.

arrow icon

What is the price predicton of ABSI Stock?

Wall Street analysts forecast ABSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABSI is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Absci Corp (ABSI)'s revenue for the last quarter?

Absci Corp revenue for the last quarter amounts to 378.00K USD, decreased -77.78 % YoY.

arrow icon

What is Absci Corp (ABSI)'s earnings per share (EPS) for the last quarter?

Absci Corp. EPS for the last quarter amounts to -0.20 USD, decreased -16.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Absci Corp (ABSI)'s fundamentals?

The market is revising Downward the revenue expectations for Absci Corporation (ABSI) for FY2025, with the revenue forecasts being adjusted by -24.26% over the past three months. During the same period, the stock price has changed by 51.63%.
arrow icon

How many employees does Absci Corp (ABSI). have?

Absci Corp (ABSI) has 156 emplpoyees as of December 05 2025.

arrow icon

What is Absci Corp (ABSI) market cap?

Today ABSI has the market capitalization of 560.89M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free